Abemaciclib Breast Cancer Survival – HR+/HER2- Treatment
Here’s a summary of the key information from the provided text about abemaciclib (Verzenio®):
What it is: Abemaciclib is a medication used to treat HR+ (hormone receptor-positive), HER2- (human epidermal growth factor receptor 2-negative) breast cancer. Initial Approval (2017): Initially approved as a single therapy for advanced or metastatic breast cancer that had progressed after hormone therapy.
Expanded Approvals:
2018: Approved in combination with an aromatase inhibitor for postmenopausal women with advanced or metastatic breast cancer.
2021 & 2023: Approved in combination with endocrine therapy (ET – tamoxifen or an aromatase inhibitor) for adjuvant treatment of high-risk, node-positive early breast cancer. MonarchE Trial: A large Phase 3 trial (5637 patients) demonstrated sustained benefits of abemaciclib plus ET in:
Overall Survival (OS)
Invasive Disease-Free Survival (IDFS) – primary endpoint
Distant Relapse-Free Survival (DRFS)
Trial Design: Patients were randomized to receive abemaciclib + ET or ET alone for 2 years.
* Current Status: Abemaciclib is considered a standard-of-care adjuvant treatment for high-risk HR+, HER2- early breast cancer, providing both survival benefits and durable disease control when combined with ET.